Xbrane Biopharma AB (publ) (XBRANE.ST)
SEK 0.16
(-3.53%)
SEK 0.16
(-3.53%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 231.47 Million SEK | 505.65% |
| 2022 | 38.22 Million SEK | -13.88% |
| 2021 | 44.38 Million SEK | 608.96% |
| 2020 | 6.26 Million SEK | -33.67% |
| 2019 | 9.43 Million SEK | -81.02% |
| 2018 | 49.72 Million SEK | 4343.34% |
| 2017 | 1.11 Million SEK | -73.89% |
| 2016 | 4.28 Million SEK | 5.47% |
| 2015 | 4.06 Million SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 124.18 Million SEK | 0.78% |
| 2024 Q2 | 169.04 Million SEK | -26.75% |
| 2024 Q1 | 230.76 Million SEK | -0.31% |
| 2023 Q4 | 231.47 Million SEK | -4.11% |
| 2023 Q1 | 40.34 Million SEK | 5.56% |
| 2023 FY | 231.47 Million SEK | 505.65% |
| 2023 Q3 | 241.4 Million SEK | -1.61% |
| 2023 Q2 | 245.34 Million SEK | 508.1% |
| 2022 FY | 38.22 Million SEK | -13.88% |
| 2022 Q3 | 40.42 Million SEK | -5.1% |
| 2022 Q2 | 42.6 Million SEK | 0.36% |
| 2022 Q1 | 42.44 Million SEK | -4.36% |
| 2022 Q4 | 38.22 Million SEK | -5.46% |
| 2021 Q1 | 47.78 Million SEK | 663.39% |
| 2021 FY | 44.38 Million SEK | 608.96% |
| 2021 Q4 | 44.38 Million SEK | -5.01% |
| 2021 Q3 | 46.72 Million SEK | 1.66% |
| 2021 Q2 | 45.95 Million SEK | -3.83% |
| 2020 Q1 | 8.7 Million SEK | -7.74% |
| 2020 Q4 | 6.26 Million SEK | -11.63% |
| 2020 Q3 | 7.08 Million SEK | -9.93% |
| 2020 FY | 6.26 Million SEK | -33.67% |
| 2020 Q2 | 7.86 Million SEK | -9.67% |
| 2019 Q2 | 6.13 Million SEK | -87.62% |
| 2019 Q1 | 49.52 Million SEK | -0.39% |
| 2019 FY | 9.43 Million SEK | -81.02% |
| 2019 Q4 | 9.43 Million SEK | -9.55% |
| 2019 Q3 | 10.43 Million SEK | 70.2% |
| 2018 Q1 | 21.03 Million SEK | 1779.45% |
| 2018 FY | 49.72 Million SEK | 4343.34% |
| 2018 Q4 | 49.72 Million SEK | -9.39% |
| 2018 Q3 | 54.87 Million SEK | 52.85% |
| 2018 Q2 | 35.9 Million SEK | 70.71% |
| 2017 Q1 | 5.35 Million SEK | 24.92% |
| 2017 Q2 | 4.41 Million SEK | -17.49% |
| 2017 Q3 | 295.32 Thousand SEK | -93.32% |
| 2017 Q4 | 1.11 Million SEK | 278.91% |
| 2017 FY | 1.11 Million SEK | -73.89% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q4 | 4.28 Million SEK | 0.0% |
| 2016 FY | 4.28 Million SEK | 5.47% |
| 2016 Q1 | - SEK | -100.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2015 Q4 | 4.06 Million SEK | 0.0% |
| 2015 FY | 4.06 Million SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 16.09 Million SEK | -1338.026% |
| Ziccum AB (publ) | 857 Thousand SEK | -26910.385% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 4.97 Million SEK | -4549.106% |
| Sprint Bioscience AB (publ) | - SEK | -Infinity% |
| Mendus AB (publ) | 24.48 Million SEK | -845.275% |
| Genovis AB (publ.) | 79.32 Million SEK | -191.829% |
| Intervacc AB (publ) | 181 Thousand SEK | -127788.95% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.61 Million SEK | -1023.085% |
| Active Biotech AB (publ) | 3 Million SEK | -7615.967% |
| Magle Chemoswed Holding AB (publ) | 60.3 Million SEK | -283.866% |
| Bio-Works Technologies AB (publ) | - SEK | -Infinity% |
| Aptahem AB (publ) | 5 Million SEK | -4529.58% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | - SEK | -Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | - SEK | -Infinity% |
| Saniona AB (publ) | 71.4 Million SEK | -224.159% |
| Lipigon Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Biovica International AB (publ) | 7.82 Million SEK | -2857.064% |
| Spago Nanomedical AB (publ) | - SEK | -Infinity% |
| AcouSort AB (publ) | - SEK | -Infinity% |
| Xintela AB (publ) | - SEK | -Infinity% |
| Abliva AB (publ) | 424 Thousand SEK | -54494.104% |
| Egetis Therapeutics AB (publ) | 108.6 Million SEK | -113.148% |
| Karolinska Development AB (publ) | 3.07 Million SEK | -7440.033% |
| OncoZenge AB (publ) | - SEK | -Infinity% |
| Amniotics AB (publ) | 2.58 Million SEK | -8872.054% |
| 2cureX AB (publ) | - SEK | -Infinity% |
| CombiGene AB (publ) | - SEK | -Infinity% |
| Asarina Pharma AB (publ) | 1 Million SEK | -23047.9% |
| Calliditas Therapeutics AB (publ) | 979.13 Million SEK | 76.359% |
| Camurus AB (publ) | 24.5 Million SEK | -844.542% |
| Corline Biomedical AB | - SEK | -Infinity% |
| IRLAB Therapeutics AB (publ) | 27.56 Million SEK | -739.726% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| I-Tech AB | - SEK | -Infinity% |
| Hansa Biopharma AB (publ) | 866.76 Million SEK | 73.294% |
| Cyxone AB (publ) | 858 Thousand SEK | -26878.904% |
| ExpreS2ion Biotech Holding AB (publ) | 1.71 Million SEK | -13428.872% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | - SEK | -Infinity% |
| Xspray Pharma AB (publ) | 36.8 Million SEK | -528.882% |
| Elicera Therapeutics AB (publ) | - SEK | -Infinity% |
| Nanologica AB (publ) | 666 Thousand SEK | -34656.607% |
| SynAct Pharma AB | 637 Thousand SEK | -36238.932% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | 850 Thousand SEK | -27132.824% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 1.76 Million SEK | -13044.747% |
| BioInvent International AB (publ) | 23.24 Million SEK | -895.866% |
| Alzinova AB (publ) | 800 Thousand SEK | -28834.875% |
| Oncopeptides AB (publ) | 106.48 Million SEK | -117.378% |
| Pila Pharma AB (publ) | 773.08 Thousand SEK | -29842.438% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | - SEK | -Infinity% |
| Simris Alg AB (publ) | 90.74 Million SEK | -155.101% |
| Diamyd Medical AB (publ) | 30.67 Million SEK | -654.692% |
| Ascelia Pharma AB (publ) | 1.06 Million SEK | -21717.059% |
| Diagonal Bio AB (publ) | - SEK | -Infinity% |